National Institute of Allergy and Infectious Diseases
Link to NIAID Home Page Link to NIAID Home Page Link to NIH Home Page
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

HIV/AIDS
 Understanding
 Research
  Basic Science
  Epidemiology
  Prevention
  Therapeutics
  Vaccines
   Introduction and Goals
   Research Activities
   Resources for Researchers
    Access to Animal Models and Vaccine Reagents
    Simian Vaccine Evaluation Units
    Vaccine Reagent Resource
   Funding
   Meetings
   Reports and Articles
   Advisory and Working Groups
   Clinical Trials
   Considerations Papers


HIV/AIDS

Requests for Use of Nonhuman Primates at Simian Vaccine Evaluation Units

Simian Vaccine Evaluation Units evaluate promising SIV and HIV vaccines in nonhuman primates in order to accelerate HIV vaccine development.

The Simian Vaccine Evaluation Units (SVEUs) provide nonhuman primates for evaluation of candidate SIV or HIV vaccines. Proposals from investigators for vaccine studies (see the guidelines for submission of proposals) are evaluated by NIAID, and approved studies are conducted at one of the three SVEU contract sites. Studies conducted at SVEUs are collaborative. The vaccine investigator will be expected to participate, with the SVEU Principal Investigator and the SVEU Project Officer, in the design of the study and in discussion and evaluation of data and results. The SVEU contractor will immunize nonhuman primates with the candidate vaccine and, together with the Primate Immunology Laboratory, can evaluate humoral and cellular immune responses. The SVEU can also challenge the animals with virus, determine whether or not the animals become infected, conduct assays to determine the levels of replicating virus, and evaluate disease outcomes. The SVEUs conduct several types of studies: (I) preliminary studies on new vaccines, (II) efficacy studies with vaccines that have already demonstrated promise, (III) studies with passively administered products, and (IV) in vivo titration of virus challenge stocks. SVEUs may also evaluate the immunogenicity and safety of candidate HIV vaccines (or SIV vaccines that parallel HIV vaccines in approach) in support of Phase I human clinical trials. In addition, the SVEUs can conduct comparative studies on vaccines and/or adjuvants from multiple sources.

Current Simian Vaccine Evaluation Unit Contractors

Advanced BioScience Laboratories
Kensington, MD
P.I.: Dr. Phil Markham

Southern Research Institute
Frederick, MD
P.I.: Dr. Mark Lewis

University of Washington
Seattle, WA
P.I.: Dr. William Morton

Current Primate Immunology Laboratory Contractors

Cellular Immune Assays:
Beth Israel Hospital
Boston, MA
P.I.: Dr. Norman Letvin
Virus Neutralization Assays:
Duke University
Durham, NC
P.I.: Dr. David Montefiori

Contact
Dr. Nancy Miller
Phone: 301-435-3753

back to top


Highlights

25 Years of HIV/AIDS Science: Reaching the Poor with Research Advances (Commentary by NIAID Director Anthony S. Fauci published in Cell)—Nov. 2, 2007

See Also

  • Division of AIDS
  • Vaccine Research Center
  • HIV/AIDS Publications
  • HIV/AIDS News Releases
  • Global Research, Africa
  • Selected NIAID Science Advances, 2007-2008 (PDF)
  • Vaccines
  • NIAID Funding News
  • E-mail Icon E-mail this page
    Print Icon Print this page

    Highlights

    25 Years of HIV/AIDS Science: Reaching the Poor with Research Advances (Commentary by NIAID Director Anthony S. Fauci published in Cell)—Nov. 2, 2007

    See Also

  • Division of AIDS
  • Vaccine Research Center
  • HIV/AIDS Publications
  • HIV/AIDS News Releases
  • Global Research, Africa
  • Selected NIAID Science Advances, 2007-2008 (PDF)
  • Vaccines
  • NIAID Funding News